Study explores whether certain brain proteins may play a role in Alzheimer's development

With a four-year, $3.3 million grant from the National Institutes of Health (NIH), researchers from Case Western Reserve University will study whether certain brain proteins may play a role in the development of Alzheimer's disease.

Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills. According to the Alzheimer's Association, nearly 7 million Americans 65 and older are living with the disease and there are more deaths from Alzheimer's than breast and prostate cancer combined.

Previous research has found evidence that Alzheimer's begins when the brain's protective barrier-;called the blood-brain barrier (BBB)-;weakens. This weakening allows harmful substances to enter the brain, which could lead to the onset of Alzheimer's.

The NIH-backed study will examine the potential function of epitope (Eph) receptors in Alzheimer's disease. Eph receptors are proteins initially investigated by Bing-Cheng Wang, a professor of pharmacology at Case Western Reserve's School of Medicine, for their role in brain development and cancer. They mediate various cell-to-cell interactions.

These proteins, according to Matthias Buck, a professor of physiology and biophysics at the School of Medicine, and his colleagues, may be involved in the BBB's disintegration, which is crucial for protecting the brain from damage during strokes and the early stages of Alzheimer's disease. The new study expands on Buck's 15 years of Eph research.

Working with Buck's lab, which is studying a part of the Eph receptor protein using advanced imaging and computational techniques, researchers from Texas Tech University and the University of Tennessee will study how this protein behaves in living cells. And scientists at Memorial Sloan Kettering Cancer Center are using crystallography to understand the protein's structure.

Alzheimer's is very complex, which is why this project requires a collaboration of special skills. Since some infectious agents can pass through the blood-brain barrier and Eph receptors are helpful, we plan to enlist the assistance of more local and national partners as this research gains momentum. We anticipate this research will result in discoveries that will one day make it possible to treat an illness that impacts millions of people worldwide."

Matthias Buck, professor of physiology and biophysics, School of Medicine, Case Western Reserve University

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation